Spotlight on Cardiology

James E. Udelson, MD, FAHA
Hypertrophic Cardiomyopathy for Professionals – Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis
James E. Udelson, MD, FAHA
American Heart Association

Hypertrophic Cardiomyopathy for Professionals – Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis

Start

This educational activity has not been certified for Continuing Medical Education credit.

Released: January 4, 2022
Expires: January 4, 2023
60 minutes to complete

Provided By

Target Audience

Clinical general cardiology audience — physicians, nurses, nurse practitioners, physician assistants

Learning Objectives

  • Identify incidence and under-diagnosis of HCM in general population
  • Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  • Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  • Discuss alternative etiologies/diagnoses to be considered
  • Discuss how genetic testing can help differentiate between diagnoses
  • Review guideline-directed care, including appropriate referral to specialists

Activity Description

HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Watch this informative webinar today and improve patient outcomes.

Statement of Educational Need

Hypertrophic cardiomyopathy is a challenging disease to diagnose and often goes undiagnosed, putting patients at risk of sudden cardiac death, heart failure, and arrhythmias.

Agenda

  1. Discuss incidence and under-diagnosis of HCM in general population
  2. Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  3. Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  4. Discuss alternative etiologies/diagnoses to be considered
  5. Discuss how genetic testing can help differentiate between diagnoses
  6. Review guideline-directed care, including appropriate referral to specialists

Moderator

James E. Udelson, MD, FAHA
Chief, Division of Cardiology
Tufts Medical Center
Boston, MA

Presenters

Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine
Associate Professor of Genetics
Washington University
St. Louis, MO


Anjali Tiku Owens, MD
Director, Penn Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA


Matthew Martinez, MD, FACC
Director, Sports Cardiology
Co-Director, Chanin T Mast Hypertrophic Cardiomyopathy Center
Morristown, NJ

Disclosures

All persons who develop and/or control educational content in activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Moderator
James E. Udelson, MD, FAHA
Disclosure – None

Presenters
Sharon Cresci, MD, FAHA, FACC, FASE
Disclosure – None

Anjali Tiku Owens, MD
Disclosure – Myokardia (now Bristol Myers Squibb)

Matthew Martinez, MD, FACC
Disclosure – Bristol Myers Squibb

This represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire, which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Statement of Commercial Support

Bristol Myers Squibb is a national supporter of the American Heart Association’s hypertrophic cardiomyopathy initiative.

Contact Information for Questions About the Activity

Please contact Sheila.Jackson@heart.org with questions about this webinar.

This educational activity has not been certified for Continuing Medical Education credit.

Released: January 4, 2022
Expires: January 4, 2023
60 minutes to complete

Provided By

Target Audience

Clinical general cardiology audience — physicians, nurses, nurse practitioners, physician assistants

Learning Objectives

  • Identify incidence and under-diagnosis of HCM in general population
  • Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  • Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  • Discuss alternative etiologies/diagnoses to be considered
  • Discuss how genetic testing can help differentiate between diagnoses
  • Review guideline-directed care, including appropriate referral to specialists

Activity Description

HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Watch this informative webinar today and improve patient outcomes.

Statement of Educational Need

Hypertrophic cardiomyopathy is a challenging disease to diagnose and often goes undiagnosed, putting patients at risk of sudden cardiac death, heart failure, and arrhythmias.

Agenda

  1. Discuss incidence and under-diagnosis of HCM in general population
  2. Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  3. Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  4. Discuss alternative etiologies/diagnoses to be considered
  5. Discuss how genetic testing can help differentiate between diagnoses
  6. Review guideline-directed care, including appropriate referral to specialists

Moderator

James E. Udelson, MD, FAHA
Chief, Division of Cardiology
Tufts Medical Center
Boston, MA

Presenters

Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine
Associate Professor of Genetics
Washington University
St. Louis, MO


Anjali Tiku Owens, MD
Director, Penn Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA


Matthew Martinez, MD, FACC
Director, Sports Cardiology
Co-Director, Chanin T Mast Hypertrophic Cardiomyopathy Center
Morristown, NJ

Disclosures

All persons who develop and/or control educational content in activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Moderator
James E. Udelson, MD, FAHA
Disclosure – None

Presenters
Sharon Cresci, MD, FAHA, FACC, FASE
Disclosure – None

Anjali Tiku Owens, MD
Disclosure – Myokardia (now Bristol Myers Squibb)

Matthew Martinez, MD, FACC
Disclosure – Bristol Myers Squibb

This represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire, which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Statement of Commercial Support

Bristol Myers Squibb is a national supporter of the American Heart Association’s hypertrophic cardiomyopathy initiative.

Contact Information for Questions About the Activity

Please contact Sheila.Jackson@heart.org with questions about this webinar.

Cardiology Presentations

James E. Udelson, MD, FAHA
American Heart Association
Hypertrophic Cardiomyopathy for Professionals – Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis

Hypertrophic Cardiomyopathy for Professionals – Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis

Start

This educational activity has not been certified for Continuing Medical Education credit.

Released: January 4, 2022
Expires: January 4, 2023
60 minutes to complete

Provided By

Target Audience

Clinical general cardiology audience — physicians, nurses, nurse practitioners, physician assistants

Learning Objectives

  • Identify incidence and under-diagnosis of HCM in general population
  • Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  • Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  • Discuss alternative etiologies/diagnoses to be considered
  • Discuss how genetic testing can help differentiate between diagnoses
  • Review guideline-directed care, including appropriate referral to specialists

Activity Description

HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Watch this informative webinar today and improve patient outcomes.

Statement of Educational Need

Hypertrophic cardiomyopathy is a challenging disease to diagnose and often goes undiagnosed, putting patients at risk of sudden cardiac death, heart failure, and arrhythmias.

Agenda

  1. Discuss incidence and under-diagnosis of HCM in general population
  2. Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  3. Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  4. Discuss alternative etiologies/diagnoses to be considered
  5. Discuss how genetic testing can help differentiate between diagnoses
  6. Review guideline-directed care, including appropriate referral to specialists

Moderator

James E. Udelson, MD, FAHA
Chief, Division of Cardiology
Tufts Medical Center
Boston, MA

Presenters

Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine
Associate Professor of Genetics
Washington University
St. Louis, MO


Anjali Tiku Owens, MD
Director, Penn Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA


Matthew Martinez, MD, FACC
Director, Sports Cardiology
Co-Director, Chanin T Mast Hypertrophic Cardiomyopathy Center
Morristown, NJ

Disclosures

All persons who develop and/or control educational content in activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Moderator
James E. Udelson, MD, FAHA
Disclosure – None

Presenters
Sharon Cresci, MD, FAHA, FACC, FASE
Disclosure – None

Anjali Tiku Owens, MD
Disclosure – Myokardia (now Bristol Myers Squibb)

Matthew Martinez, MD, FACC
Disclosure – Bristol Myers Squibb

This represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire, which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Statement of Commercial Support

Bristol Myers Squibb is a national supporter of the American Heart Association’s hypertrophic cardiomyopathy initiative.

Contact Information for Questions About the Activity

Please contact Sheila.Jackson@heart.org with questions about this webinar.

This educational activity has not been certified for Continuing Medical Education credit.

Released: January 4, 2022
Expires: January 4, 2023
60 minutes to complete

Provided By

Target Audience

Clinical general cardiology audience — physicians, nurses, nurse practitioners, physician assistants

Learning Objectives

  • Identify incidence and under-diagnosis of HCM in general population
  • Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  • Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  • Discuss alternative etiologies/diagnoses to be considered
  • Discuss how genetic testing can help differentiate between diagnoses
  • Review guideline-directed care, including appropriate referral to specialists

Activity Description

HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Watch this informative webinar today and improve patient outcomes.

Statement of Educational Need

Hypertrophic cardiomyopathy is a challenging disease to diagnose and often goes undiagnosed, putting patients at risk of sudden cardiac death, heart failure, and arrhythmias.

Agenda

  1. Discuss incidence and under-diagnosis of HCM in general population
  2. Identify diagnostic criteria and summarize appropriate diagnostic testing needed for accurate diagnosis and relevant findings that are suggestive of specific diagnoses
  3. Recognize common patient symptoms and clinical clues pointing to an HCM diagnosis
  4. Discuss alternative etiologies/diagnoses to be considered
  5. Discuss how genetic testing can help differentiate between diagnoses
  6. Review guideline-directed care, including appropriate referral to specialists

Moderator

James E. Udelson, MD, FAHA
Chief, Division of Cardiology
Tufts Medical Center
Boston, MA

Presenters

Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine
Associate Professor of Genetics
Washington University
St. Louis, MO


Anjali Tiku Owens, MD
Director, Penn Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA


Matthew Martinez, MD, FACC
Director, Sports Cardiology
Co-Director, Chanin T Mast Hypertrophic Cardiomyopathy Center
Morristown, NJ

Disclosures

All persons who develop and/or control educational content in activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Moderator
James E. Udelson, MD, FAHA
Disclosure – None

Presenters
Sharon Cresci, MD, FAHA, FACC, FASE
Disclosure – None

Anjali Tiku Owens, MD
Disclosure – Myokardia (now Bristol Myers Squibb)

Matthew Martinez, MD, FACC
Disclosure – Bristol Myers Squibb

This represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire, which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Statement of Commercial Support

Bristol Myers Squibb is a national supporter of the American Heart Association’s hypertrophic cardiomyopathy initiative.

Contact Information for Questions About the Activity

Please contact Sheila.Jackson@heart.org with questions about this webinar.